USPTO to Re-examine ExonHit Patent | GenomeWeb
NEW YORK (GenomeWeb News) – Jivan Biologics said yesterday that the US Patent and Trademark Office will re-examine a patent held by Paris-based ExonHit Therapeutics covering methods for identifying differentially spliced gene products.
The patent, No. 6,881,571, is at the center of a patent infringement suit filed last year by ExonHit against Larkspur, Calif.-based Jivan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.